In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on 89bio (ETNB – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $8.97.
According to TipRanks, Abrahams is a 4-star analyst with an average return of 7.4% and a 50.10% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, PTC Therapeutics, and SAGE Therapeutics.
In addition to RBC Capital, 89bio also received a Hold from Oppenheimer’s Jay Olson in a report issued on May 14. However, yesterday, H.C. Wainwright maintained a Buy rating on 89bio (NASDAQ: ETNB).
The company has a one-year high of $22.93 and a one-year low of $6.58. Currently, 89bio has an average volume of 1.07M.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ETNB in relation to earlier this year. Last month, Ra Capital Management, Llc, a Director at ETNB bought 1,408,450.00 shares for a total of $7,492,954.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio (ETNB) Company Description:
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Read More on ETNB:
